PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of PG2 concurrent with
concurrent chemoradiation therapy (CCRT) for relieving fatigue among locally advanced
esophageal cancer patients who are under preoperative chemoradiation therapy at curative
setting. This study will be designed to compare the fatigue status between two study arms
patients under CCRT.
The secondary objective is to assess the efficacy of PG2 to improve the quality of life of
patient during CCRT. Also, the investigators try to determine the effect of PG2 on tumor
response post CCRT, disease free survival (DFS) and overall survival (OS) of patients by
comparing the above outcome between the two study arms.
The mechanism of immunomodulatory of PG2 and tumor response, DFS and OS for patients with
esophageal cancer treated with preoperative CCRT concurrent with or without PG2 will be
investigated in add-on study.